Total Payments
$36,997
2024 Payments
$21,342
Companies
23
Transactions
74
Medicare Patients
458
Medicare Billing
$75,477
Payment Breakdown by Category
Other$16,081 (43.5%)
Consulting$10,525 (28.4%)
Travel$5,923 (16.0%)
Research$2,415 (6.5%)
Food & Beverage$2,037 (5.5%)
Education$16.24 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,181 | 4 | 41.0% |
| Consulting Fee | $10,525 | 3 | 28.4% |
| Travel and Lodging | $5,923 | 14 | 16.0% |
| Unspecified | $2,415 | 10 | 6.5% |
| Food and Beverage | $2,037 | 41 | 5.5% |
| Honoraria | $900.00 | 1 | 2.4% |
| Education | $16.24 | 1 | 0.0% |
Payments by Type
General
$34,582
64 transactions
Research
$2,415
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $19,123 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $8,145 | 3 | $0 (2021) |
| Siemens Medical Solutions USA, Inc. | $2,926 | 10 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $2,477 | 4 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,087 | 1 | $0 (2020) |
| ABBVIE INC. | $1,004 | 8 | $0 (2023) |
| Coherus Biosciences Inc. | $900.00 | 1 | $0 (2021) |
| F. Hoffmann-La Roche AG | $434.27 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $175.50 | 1 | $0 (2019) |
| Exelixis Inc. | $157.68 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,342 | 17 | Ipsen Biopharmaceuticals, Inc ($18,942) |
| 2023 | $1,199 | 11 | ABBVIE INC. ($1,004) |
| 2022 | $2,405 | 11 | Siemens Medical Solutions USA, Inc. ($2,321) |
| 2021 | $9,657 | 6 | Novartis Pharmaceuticals Corporation ($8,125) |
| 2020 | $1,158 | 5 | Regeneron Pharmaceuticals, Inc. ($1,087) |
| 2019 | $441.86 | 14 | Boehringer Ingelheim Pharmaceuticals, Inc. ($175.50) |
| 2018 | $205.26 | 8 | Exelixis Inc. ($80.73) |
| 2017 | $589.85 | 2 | F. Hoffmann-La Roche AG ($434.27) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 09/10/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $145.90 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,306.50 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $373.34 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $357.96 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $56.70 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $42.00 | General |
| Category: Oncology | ||||||
| 05/20/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,220.00 | General |
| Category: Oncology | ||||||
| 05/20/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $1,285.18 | General |
| Category: Oncology | ||||||
| 05/20/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $93.77 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $125.25 | General |
| Category: Oncology | ||||||
| 03/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $206.41 | General |
| Category: Oncology | ||||||
| 03/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 03/01/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $1,024.00 | General |
| Category: Oncology | ||||||
| 03/01/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,220.00 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $295.00 | General |
| Category: Oncology | ||||||
| 11/11/2023 | AbbVie Inc. | — | — | In-kind items and services | $466.31 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/11/2023 | AbbVie Inc. | — | — | In-kind items and services | $53.54 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/11/2023 | AbbVie Inc. | — | — | In-kind items and services | $31.13 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/11/2023 | AbbVie Inc. | — | — | In-kind items and services | $18.68 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/10/2023 | AbbVie Inc. | — | — | In-kind items and services | $165.30 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/10/2023 | AbbVie Inc. | — | — | In-kind items and services | $96.06 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 11/09/2023 | AbbVie Inc. | — | — | In-kind items and services | $165.30 | Research |
| Study: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | ||||||
| 10/24/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $7.53 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,087 | 1 |
| Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | AbbVie Inc. | $996.32 | 7 |
| BI754111 & BI754091 BI75411 combination | Boehringer Ingelheim Pharmaceuticals, Inc. | $175.50 | 1 |
| Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment | SANOFI-AVENTIS U.S. LLC | $155.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 103 | 165 | $58,014 | $15,706 |
| 2022 | 4 | 112 | 250 | $79,102 | $22,572 |
| 2021 | 2 | 58 | 102 | $30,450 | $8,649 |
| 2020 | 6 | 185 | 362 | $124,386 | $28,550 |
Total Patients
458
Total Services
879
Medicare Billing
$75,477
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 66 | $25,674 | $6,968 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 70 | $18,130 | $4,784 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $14,210 | $3,954 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 99 | $36,971 | $10,507 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 94 | $22,978 | $6,729 | 29.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $14,870 | $4,060 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 25 | $4,283 | $1,276 | 29.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 54 | $14,738 | $4,138 | 28.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 22 | $7,938 | $2,530 | 31.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 26 | $7,774 | $1,980 | 25.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 45 | 144 | $43,056 | $9,775 | 22.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 34 | 73 | $21,827 | $5,149 | 23.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 32 | $12,768 | $2,927 | 22.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $11,880 | $2,735 | 23.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 23 | $9,867 | $2,192 | 22.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $9,396 | $2,135 | 22.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 17 | $7,293 | $1,686 | 23.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 28 | $5,404 | $1,291 | 23.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 15 | $2,895 | $659.77 | 22.8% |
About Dr. Albert Lockhart, MD
Dr. Albert Lockhart, MD is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437233533.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Albert Lockhart, MD has received a total of $36,997 in payments from pharmaceutical and medical device companies, with $21,342 received in 2024. These payments were reported across 74 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($15,181).
As a Medicare-enrolled provider, Lockhart has provided services to 458 Medicare beneficiaries, totaling 879 services with total Medicare billing of $75,477. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Charleston, SC
- Active Since 10/25/2006
- Last Updated 03/02/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437233533
Products in Payments
- Onivyde (Drug) $18,942
- Varian Treatment (Device) $1,278
- LIBTAYO (Biological) $1,087
- Zelboraf (Biological) $434.27
- Somatuline Depot (Drug) $180.93
- JEVTANA (Drug) $155.58
- Cabometyx (Drug) $80.73
- OPDIVO (Biological) $77.41
- KEYTRUDA (Biological) $60.56
- SUTENT (Drug) $31.48
- IMFINZI (Drug) $25.90
- Non-Covered Product (Drug) $22.80
- SANDOSTATIN LAR (Drug) $20.06
- Reblozyl (Drug) $19.36
- ADCETRIS (Biological) $18.97
- INJECTAFER (Drug) $18.64
- MVASI (Biological) $17.30
- INLYTA (Drug) $16.65
- FOUNDATIONONE (Device) $16.15
- BAVENCIO (Drug) $15.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. George Geils, M.d, M.D
Hematology & Oncology — Payments: $184,021
Hematology & Oncology $184,021
Mr. David Ellison, M.d, M.D
Hematology & Oncology — Payments: $39,035
Hematology & Oncology $39,035
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Dr. Brian Lingerfelt, Md, MD
Hematology & Oncology — Payments: $30,721
Hematology & Oncology $30,721
Robert Stuart, Md, MD
Hematology & Oncology — Payments: $25,933
Hematology & Oncology $25,933
Dr. George Keogh, M.d, M.D
Hematology & Oncology — Payments: $18,248
Hematology & Oncology $18,248